PRE

Prenetics Global

Fundamental data last updated:April 13, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Diagnostics & Research

Exchange

Nasdaq

County of HQ

Hong Kong

Next Earnings Date

06/11/26

Business Summary

Prenetics Global operates in diagnostics and research, generating revenue through medical testing services and related healthcare solutions. Its model depends on scaling laboratory operations and monetizing diagnostic data while managing cost-intensive infrastructure. The moat, if any, lies in regulatory positioning, brand credibility in healthcare testing, and integration of technology into diagnostics workflows. Cash generation ultimately hinges on improving operating efficiency and converting testing volume into sustainable positive margins rather than relying on external capital.

 


Analyze PRE on TradingView

VALUATION

P/E

-

Market Cap ($M USD)

$299

Forward P/E

-

PEG

-

PRICE TO SALES

2.7

PRICE TO BOOK

1.7

EV / EBITDA

-4.1

5-Year Average P/E

Free Cash Flow Yield

DCF Value

Graham Number

Price to FCF

EV to FCF

Earnings Yield

FCF Yield

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$3.59

Next Year EPS Growth Estimate

-$0.68

Next Year Revenue Growth Estimate

59.50%

Return on Equity (ROE)

-28.90%

FREE CASH FLOW

Operating Margin

-66.10%

Debt-to-Equity

0

Piotroski F-Score

5

Altman Z-Score

5

Return on Invested Capital (ROIC)

-28.30%

Current Ratio

2.7

Quick Ratio

Net Debt to EBITDA

Interest Coverage

Gross Profit margin

FCF PER SHARE

REVENUE PER SHARE

Analyze PRE on TradingView

Gainseekers Quantitative Analysis

Summary

This is a highly speculative small-cap healthcare name with clear operating distress masked by balance sheet stability. The absence of P/E and Forward P/E reflects ongoing losses, with EPS at -4.1 and next year estimated at -$3.59, meaning there is no earnings-based valuation floor. However, the Altman Z-Score of 5 signals strong solvency and low bankruptcy risk despite negative operating metrics, suggesting the balance sheet is not the immediate problem. At 2.7x sales and 1.7x book with a $299M market cap, the market is pricing in survival but not profitable growth—this is a turnaround bet, not a compounder.

AI Exposure / Tech Reliance

As a Diagnostics & Research company, it operates in a segment increasingly influenced by data analytics, genomics, and AI-driven interpretation. The sector’s evolution toward precision diagnostics and automated lab workflows structurally favors tech-enabled operators. However, with operating margin at -28.90%, execution—not industry tailwinds—will determine whether it can capitalize on that shift.

The Bull Case

A deep value or GARP investor could argue the balance sheet strength is the hidden asset here. A Current Ratio of 2.7 combined with an Altman Z-Score of 5 indicates liquidity stability, giving management time to fix operations. The Piotroski F-Score of 5 suggests middling but not collapsing fundamentals, and Price/Book at 1.7 is not stretched for a healthcare diagnostics platform. If losses narrow from EPS -4.1 to an estimated -$3.59 and operating leverage improves from the current -28.90% margin, even modest margin normalization could dramatically re-rate a $299M company trading at 2.7x sales.

The Bear Case

The structural issues are severe: ROIC at -28.30% and operating margin at -28.90% indicate persistent capital destruction. EPS remains deeply negative with no visibility into positive earnings, and both P/E and Forward P/E are nonexistent, eliminating any traditional valuation anchor. Debt/Equity at -66.10% is distorted by capital structure dynamics, but combined with a Return on Equity of 59.50%, it signals volatility in equity returns rather than stable profitability. With no dividend, no yield, and unclear growth metrics, investors are entirely dependent on a turnaround that has yet to materialize.

Market Sentiment & Smart Money

Short Interest %

3.80%

Analyst Consensus

1

Average Analyst Price Target

$31.25

Institutional Ownership %

13.90%

1-Year Beta

0.34

Insider Buying % (6 Mo)

18.20%%

Distance to 52-Week High

75.00%

Distance to 52-Week Low

513.90%

EARNINGS SURPRISE %

50-DAY SMA

200-DAY SMA

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.